Homogeneous antibody-angiopep 2 conjugates for effective brain targeting.

Abstract

Antibody-based therapy has shown great success in the treatment of many diseases, including cancers. While antibodies and antibody-drug conjugates (ADCs) have also been evaluated for central nervous system (CNS) disorders as well as brain tumors, their therapeutic efficacy can be substantially limited due to low permeability across the blood-brain barrier (BBB). Thus, improving BBB permeability of therapeutic antibodies is critical in establishing this drug class as a reliable clinical option for CNS diseases. Here, we report that, compared with a conventional heterogeneous conjugation, homogeneous conjugation of the synthetic BBB shuttle peptide angiopep-2 (Ang2) to a monoclonal antibody (mAb) provides improved binding affinity for brain microvascular endothelial cells in vitro and accumulation into normal brain tissues in vivo. In a mouse model, we also demonstrate that the homogeneous anti-EGFR mAb-Ang2 conjugate administered intravenously efficiently accumulates in intracranial tumors. These findings suggest that homogeneous conjugation of BBB shuttle peptides such as Ang2 is a promising approach to enhancing the therapeutic efficacy of antibody agents for CNS diseases.

• Authors: Yasuaki Anami, Wei Xiong, Aiko Yamaguchi, Chisato M Yamazaki, Ningyan Zhang, Zhiqiang An, Kyoji Tsuchikama
• Journal: RSC advances (RSC Adv) Vol. 12 Issue 6 Pg. 3359-3364 (Jan 24 2022) ISSN: 2046-2069 [Electronic] England
• PMID: 35425350 (Publication Type: Journal Article)
• Copyright: This journal is © The Royal Society of Chemistry.